Amani Therapeutics
PrivateLast Round
Series A
Mar 23, 2026
Total Funding Raised
$25.4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Amani Therapeutics is a biotechnology company developing AM-01, a fixed-dose combination therapy for serious neuropsychiatric disorders including treatment-resistant schizophrenia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amani Therapeutics Comparables
Compare Amani Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tortugas Neuroscience | 77% | |
| LB Pharmaceuticals | 76% | |
| Terran Biosciences | 73% | |
Amani Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 23, 2026 |
Amani Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RTW Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 23, 2026
$25M round completed.
Amani Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Amani Therapeutics's valuation, stock price, and market status.